- Home
- FGF vs PTN Comparison
FGF vs PTN Comparison
Compare FGF & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- PTN
- Stock Information
- Founded
- FGF 2012
- PTN 1986
- Country
- FGF United States
- PTN United States
- Employees
- FGF N/A
- PTN N/A
- Industry
- FGF Property-Casualty Insurers
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- PTN Health Care
- Exchange
- FGF Nasdaq
- PTN Nasdaq
- Market Cap
- FGF 29.0M
- PTN 25.4M
- IPO Year
- FGF N/A
- PTN 1993
- Fundamental
- Price
- FGF $20.20
- PTN $1.00
- Analyst Decision
- FGF
- PTN Strong Buy
- Analyst Count
- FGF 0
- PTN 1
- Target Price
- FGF N/A
- PTN $7.00
- AVG Volume (30 Days)
- FGF 17.4K
- PTN 1.7M
- Earning Date
- FGF 03-13-2025
- PTN 02-13-2025
- Dividend Yield
- FGF N/A
- PTN N/A
- EPS Growth
- FGF N/A
- PTN N/A
- EPS
- FGF N/A
- PTN N/A
- Revenue
- FGF $22,351,000.00
- PTN $350,000.00
- Revenue This Year
- FGF N/A
- PTN N/A
- Revenue Next Year
- FGF N/A
- PTN N/A
- P/E Ratio
- FGF N/A
- PTN N/A
- Revenue Growth
- FGF N/A
- PTN N/A
- 52 Week Low
- FGF $14.21
- PTN $0.68
- 52 Week High
- FGF $38.50
- PTN $3.99
- Technical
- Relative Strength Index (RSI)
- FGF 43.45
- PTN 50.51
- Support Level
- FGF $19.89
- PTN $0.99
- Resistance Level
- FGF $22.50
- PTN $1.08
- Average True Range (ATR)
- FGF 0.96
- PTN 0.14
- MACD
- FGF -0.10
- PTN 0.01
- Stochastic Oscillator
- FGF 9.33
- PTN 35.59
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segment includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.